Zetia vs Repatha: Cost, Access, and Clinical Outcomes Head-to-Head

How They Lower LDL: Two Different Mechanisms

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing dietary and biliary cholesterol absorption by about 54% [1]. The net effect is a 15% to 25% drop in LDL-C when added to a statin, depending on baseline levels and the statin dose already in use. Evolocumab is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), preventing it from degrading hepatic LDL receptors [2].

By keeping more LDL receptors active on liver cell surfaces, evolocumab pulls circulating LDL out of the bloodstream with dramatic efficiency. In the FOURIER trial (N=27,564), evolocumab lowered LDL-C by a median of 59% from baseline, bringing the median achieved LDL-C to 30 mg/dL [2]. That level of reduction is roughly two and a half times what ezetimibe achieves. For patients whose LDL needs to drop only modestly (say, from 95 mg/dL to 70 mg/dL on a high-intensity statin), ezetimibe alone can close the gap. When the deficit is 50% or more of the current value, evolocumab becomes the practical option.

The 2018 AHA/ACC Cholesterol Clinical Practice Guideline positions these drugs sequentially: maximize statin first, add ezetimibe second, and reserve PCSK9 inhibitors for patients whose LDL-C remains above threshold after both [3]. This stepwise approach reflects both clinical evidence and the reality of cost and access.

Cardiovascular Outcomes: What the Trials Actually Show

No head-to-head randomized trial has directly compared ezetimibe to evolocumab. The evidence comes from two large, separate outcome studies run in overlapping but different populations.

IMPROVE-IT (N=18,144) enrolled patients within 10 days of an acute coronary syndrome event and randomized them to simvastatin 40 mg plus ezetimibe 10 mg or simvastatin 40 mg plus placebo [1]. Over a median follow-up of 6 years, the ezetimibe group experienced a 6.4% relative reduction in the primary composite endpoint of cardiovascular death, major coronary events, and nonfatal stroke (32.7% vs. 34.7%, hazard ratio 0.936, P=0.016). The absolute risk reduction was 2.0 percentage points. This trial proved a principle: lowering LDL-C below 70 mg/dL with a non-statin agent produces incremental benefit.

FOURIER (N=27,564) enrolled patients with established atherosclerotic cardiovascular disease (ASCVD) already on optimized statin therapy and randomized them to evolocumab 140 mg every 2 weeks (or 420 mg monthly) versus placebo [2]. At a median follow-up of 2.2 years, the evolocumab group showed a 15% relative reduction in the primary composite endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization (9.8% vs. 11.3%, hazard ratio 0.85, P<0.001). The absolute risk reduction was 1.5 percentage points.

The difference in relative risk reduction (15% vs. 6.4%) partly reflects the much larger LDL reduction with evolocumab. But interpreting these numbers side by side requires caution. FOURIER's follow-up was shorter, its patient population was more stable, and its primary endpoint included a broader set of events. A longer FOURIER trial might have shown an even wider gap, or cardiovascular death (which did not reach significance in FOURIER at 2.2 years) might have separated. Dr. Robert Giugliano, a TIMI Study Group investigator who worked on both trials, has stated: "The LDL hypothesis is consistent across both studies. Per unit of LDL lowering, the benefit tracks the same regression line regardless of the drug class used" [4].

Cost Comparison: The Price Gap Is Massive

This is where the two drugs diverge most. Ezetimibe lost patent protection in 2016, and generic versions are widely available.

A 30-day supply of generic ezetimibe 10 mg costs between $8 and $30 at retail pharmacies, with GoodRx-type discount programs frequently bringing it below $15 [5]. Most Medicare Part D and commercial plans cover generic ezetimibe on Tier 1 or Tier 2 with copays of $0 to $15. No prior authorization is needed. Patients can walk into a pharmacy, hand over a prescription, and fill it in minutes.

Repatha's wholesale acquisition cost (WAC) sits at approximately $5,850 per year. Amgen reduced this from the original $14,100 list price in 2018 after payer pushback [6]. Even after the reduction, the out-of-pocket burden without insurance assistance is substantial. With Amgen's copay card program, commercially insured patients may pay as little as $5 per month, but the card has annual limits and does not cover patients on government insurance (Medicare, Medicaid, Tricare). Medicare Part D patients using Repatha often face specialty tier copays of 25% to 33% of the negotiated price, which can mean $150 to $400 per month depending on the plan's benefit phase.

The per-QALY economics tell a similar story. A 2017 analysis by the Institute for Clinical and Economic Review (ICER) estimated the cost-effectiveness of PCSK9 inhibitors at approximately $450,000 per QALY at their original list price, well above the commonly cited $50,000 to $150,000 per QALY threshold [7]. After the price cut to $5,850 per year, updated models brought the estimate down to roughly $85,000 to $140,000 per QALY for high-risk ASCVD patients, a range that some payers now consider acceptable [8].

Ezetimibe, by contrast, has been estimated at under $20,000 per QALY since generic availability, making it one of the most cost-effective lipid-lowering options after generic statins.

Insurance Access and Prior Authorization

Getting ezetimibe covered requires almost no administrative effort. Generic ezetimibe sits on standard formularies with minimal or no step therapy requirements. A cardiologist, internist, or primary care physician can prescribe it, and the patient fills it immediately.

Repatha access involves a different process entirely. Nearly every commercial insurer and Medicare Part D plan requires prior authorization [9]. The typical requirements include documentation that the patient has tried and failed (or is intolerant to) a maximally tolerated statin, documented LDL-C above a plan-specific threshold (often 70 mg/dL for ASCVD patients or 100 mg/dL for primary prevention), and in many cases, evidence that ezetimibe has also been tried and was insufficient. Some plans require letters of medical necessity, chart notes showing statin intolerance symptoms, or lab work within 90 days.

The prior authorization approval rate for PCSK9 inhibitors has improved since their launch but remains a friction point. A 2020 analysis in JAMA Cardiology found that approximately 50% of initial prior authorization requests for PCSK9 inhibitors were denied, and of those, only about 45% were overturned on appeal [10]. For busy clinical practices, the paperwork burden can consume 30 to 60 minutes of staff time per request.

Some health systems have addressed this with dedicated specialty pharmacy liaisons who manage the authorization workflow. Large cardiology practices may employ staff whose primary role is handling PCSK9 inhibitor authorizations. These realities mean that even when a patient clinically qualifies for Repatha, they may wait weeks for coverage approval, or they may never receive the drug at all if the denial is not appealed.

Who Should Get Which Drug?

Guidelines from the AHA/ACC (2018, updated 2022) provide a clear algorithm [3]. After maximally tolerated statin therapy, the first non-statin add-on for patients who have not reached their LDL-C goal is ezetimibe. This recommendation reflects the drug's low cost, strong safety profile, ease of use, and the outcome data from IMPROVE-IT.

PCSK9 inhibitors like evolocumab are recommended for patients whose LDL-C remains elevated after both a maximally tolerated statin and ezetimibe [3]. Specific clinical scenarios where PCSK9 inhibitor use is considered reasonable include: ASCVD patients with LDL-C 70 mg/dL or above despite statin plus ezetimibe, patients with heterozygous familial hypercholesterolemia (HeFH) not at goal, and very high-risk patients (defined as those with multiple major ASCVD events or one major event plus multiple high-risk conditions).

The 2023 European Society of Cardiology (ESC) guidelines are somewhat more aggressive, recommending PCSK9 inhibitors for very-high-risk patients who fail to reach LDL-C goals of 55 mg/dL or below, even allowing PCSK9 inhibitors without a mandatory ezetimibe trial first in selected cases [11].

A practical clinical framework: if a patient on rosuvastatin 40 mg has an LDL-C of 85 mg/dL and needs to reach 70 mg/dL, ezetimibe will likely get them there (expected reduction of about 15 to 20 mg/dL). If their LDL-C is 130 mg/dL and the target is 70 mg/dL, ezetimibe alone will not bridge that 60-point gap, and evolocumab (expected reduction of about 75 to 80 mg/dL from that baseline) becomes the necessary choice.

Safety and Tolerability

Both drugs carry favorable safety profiles, but the nature of their side effects differs.

Ezetimibe's most common adverse effects in clinical trials were upper respiratory tract infection, diarrhea, arthralgia, sinusitis, and pain in extremity, all occurring at rates similar to placebo [1]. Elevations in hepatic transaminases have been reported when ezetimibe is combined with a statin, but the rate is comparable to statin monotherapy. Myalgia is rare. The drug has been on the market since 2002, providing over two decades of post-marketing safety data.

Evolocumab's safety in FOURIER showed injection-site reactions in 2.1% of patients (vs. 1.6% for placebo) and nasopharyngitis in 10.3% [2]. Early concerns about neurocognitive effects at very low LDL-C levels were addressed by the EBBINGHAUS substudy (N=1,974), which found no difference in cognitive function between evolocumab and placebo groups despite achieved LDL-C levels of 30 mg/dL [12]. The open-label extension of FOURIER (FOURIER-OLE) showed consistent safety through 5 years of follow-up, with no new safety signals and a suggestion of continued cardiovascular benefit over time [13].

Injection burden is a real-world consideration. Some patients strongly prefer oral medications. The evolocumab autoinjector (SureClick) is pre-filled and takes about 10 seconds to administer, but needle aversion or difficulty with self-injection can limit adherence. Ezetimibe's once-daily pill is essentially no different from taking an extra statin tablet.

Combination Strategies and Emerging Options

Some patients benefit from all three layers: statin plus ezetimibe plus a PCSK9 inhibitor. In FOURIER, 5.2% of patients were already taking ezetimibe at baseline, and the benefit of adding evolocumab was consistent regardless of background ezetimibe use [2]. Triple therapy can achieve LDL-C levels below 25 mg/dL in many patients.

Bempedoic acid (Nexletol), an oral ATP citrate lyase inhibitor, has emerged as another option between ezetimibe and PCSK9 inhibitors in terms of both LDL reduction (approximately 18% added to statin) and cost (roughly $400 to $500/month at list) [14]. The CLEAR Outcomes trial showed a 13% reduction in major adverse cardiovascular events in statin-intolerant patients [15]. Inclisiran (Leqvio), a small interfering RNA targeting PCSK9, offers a twice-yearly injection schedule with similar LDL reduction to evolocumab, and may simplify access through buy-and-bill physician administration rather than specialty pharmacy distribution.

The lipid-lowering field is no longer a binary choice. But for most patients working through the guideline algorithm, the decision starts with this question: is ezetimibe enough to close the LDL gap? If yes, stop there. The annual savings compared to a PCSK9 inhibitor exceed $5,000. If not, escalate to evolocumab or alirocumab, manage the prior authorization process, and use manufacturer copay assistance where available.

A patient on atorvastatin 80 mg with an LDL-C of 72 mg/dL and a target of 70 mg/dL should take ezetimibe. A patient on the same statin with an LDL-C of 118 mg/dL after a second myocardial infarction should start the PCSK9 inhibitor authorization process immediately, with ezetimibe added in parallel while waiting for approval.